236 related articles for article (PubMed ID: 26343112)
1. Targeting the NF-κB pathway in prostate cancer: a promising therapeutic approach?
Verzella D; Fischietti M; Capece D; Vecchiotti D; Del Vecchio F; Cicciarelli G; Mastroiaco V; Tessitore A; Alesse E; Zazzeroni F
Curr Drug Targets; 2016; 17(3):311-20. PubMed ID: 26343112
[TBL] [Abstract][Full Text] [Related]
2. Targeting Oncogenic Nuclear Factor Kappa B Signaling with Redox-Active Agents for Cancer Treatment.
Fouani L; Kovacevic Z; Richardson DR
Antioxid Redox Signal; 2019 Mar; 30(8):1096-1123. PubMed ID: 29161883
[TBL] [Abstract][Full Text] [Related]
3. NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.
Yu L; Li L; Medeiros LJ; Young KH
Blood Rev; 2017 Mar; 31(2):77-92. PubMed ID: 27773462
[TBL] [Abstract][Full Text] [Related]
4. Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer.
Nguyen DP; Li J; Yadav SS; Tewari AK
BJU Int; 2014 Aug; 114(2):168-76. PubMed ID: 24215139
[TBL] [Abstract][Full Text] [Related]
5. TNF-alpha/IL-1/NF-kappaB transduction pathway in human cancer prostate.
Royuela M; Rodríguez-Berriguete G; Fraile B; Paniagua R
Histol Histopathol; 2008 Oct; 23(10):1279-90. PubMed ID: 18712680
[TBL] [Abstract][Full Text] [Related]
6. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB.
Kim SM; Lee SY; Cho JS; Son SM; Choi SS; Yun YP; Yoo HS; Yoon DY; Oh KW; Han SB; Hong JT
Eur J Pharmacol; 2010 Apr; 631(1-3):1-9. PubMed ID: 20056115
[TBL] [Abstract][Full Text] [Related]
7. Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor-κB Signaling for Cancer Treatment.
Zeligs KP; Neuman MK; Annunziata CM
Clin Cancer Res; 2016 Sep; 22(17):4302-8. PubMed ID: 27422962
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis.
Wilson C; Purcell C; Seaton A; Oladipo O; Maxwell PJ; O'Sullivan JM; Wilson RH; Johnston PG; Waugh DJ
J Pharmacol Exp Ther; 2008 Dec; 327(3):746-59. PubMed ID: 18780829
[TBL] [Abstract][Full Text] [Related]
9. Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model.
Shukla S; Maclennan GT; Marengo SR; Resnick MI; Gupta S
Prostate; 2005 Aug; 64(3):224-39. PubMed ID: 15712212
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB.
Raj GV; Sekula JA; Guo R; Madden JF; Daaka Y
Prostate; 2004 Oct; 61(2):105-13. PubMed ID: 15305333
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway.
Ren D; Yang Q; Dai Y; Guo W; Du H; Song L; Peng X
Mol Cancer; 2017 Jul; 16(1):117. PubMed ID: 28693582
[TBL] [Abstract][Full Text] [Related]
12. Regulation of cell survival by resveratrol involves inhibition of NF kappa B-regulated gene expression in prostate cancer cells.
Benitez DA; Hermoso MA; Pozo-Guisado E; Fernández-Salguero PM; Castellón EA
Prostate; 2009 Jul; 69(10):1045-54. PubMed ID: 19301309
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-mediated inhibition of NF-kappaB confers chemo-sensitization and apoptosis in prostate cancer cells.
Flynn V; Ramanitharan A; Moparty K; Davis R; Sikka S; Agrawal KC; Abdel-Mageed AB
Int J Oncol; 2003 Aug; 23(2):317-23. PubMed ID: 12851680
[TBL] [Abstract][Full Text] [Related]
15. Id-1 expression promotes cell survival through activation of NF-kappaB signalling pathway in prostate cancer cells.
Ling MT; Wang X; Ouyang XS; Xu K; Tsao SW; Wong YC
Oncogene; 2003 Jul; 22(29):4498-508. PubMed ID: 12881706
[TBL] [Abstract][Full Text] [Related]
16. Lysophosphatidic acid activates the RhoA and NF-κB through Akt/IκBα signaling and promotes prostate cancer invasion and progression by enhancing functional invadopodia formation.
Hwang YS; Lee J; Zhang X; Lindholm PF
Tumour Biol; 2016 May; 37(5):6775-85. PubMed ID: 26662305
[TBL] [Abstract][Full Text] [Related]
17. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon?
Suh J; Rabson AB
J Cell Biochem; 2004 Jan; 91(1):100-17. PubMed ID: 14689584
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
[TBL] [Abstract][Full Text] [Related]
19. NF-κB in cancer therapy.
Li F; Zhang J; Arfuso F; Chinnathambi A; Zayed ME; Alharbi SA; Kumar AP; Ahn KS; Sethi G
Arch Toxicol; 2015 May; 89(5):711-31. PubMed ID: 25690730
[TBL] [Abstract][Full Text] [Related]
20. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen.
Palayoor ST; Youmell MY; Calderwood SK; Coleman CN; Price BD
Oncogene; 1999 Dec; 18(51):7389-94. PubMed ID: 10602496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
